AGM
AMAM

Alpine Global Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Alpine Global Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46,723
Closed -$106K – 486
2022
Q4 		$106K Buy
+46,723
New +$53.4K 0.04% 248

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Alpine Global Management's AMAM Position: Q1 2023 in Review

Alpine Global Management sold out of Ambrx Biopharma Inc (AMAM) in Q1 2023, closing a stake of 46,723 shares — an estimated $106K sold.

Alpine Global Management first reported a position in AMAM in Q4 2022 and held it in 1 quarter. The position peaked at $106K in Q4 2022. 30 funds tracked by Wall St. Rank hold AMAM as of Q1 2023.

  • Alpine Global Management reported no remaining Ambrx Biopharma Inc position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 46,723 Ambrx Biopharma Inc shares in Q1 2023, an estimated $106K.
  • Alpine Global Management first reported a position in Ambrx Biopharma Inc in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Ambrx Biopharma Inc position peaked at $106K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.